Reviewing NuVasive (NASDAQ:NUVA) and Bluejay Diagnostics (NASDAQ:BJDX)

NuVasive (NASDAQ:NUVAGet Rating) and Bluejay Diagnostics (NASDAQ:BJDXGet Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Earnings and Valuation

This table compares NuVasive and Bluejay Diagnostics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NuVasive $1.14 billion 2.05 -$64.09 million ($0.42) -106.64
Bluejay Diagnostics N/A N/A -$3.49 million ($0.44) -1.11

Bluejay Diagnostics has lower revenue, but higher earnings than NuVasive. NuVasive is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.


This table compares NuVasive and Bluejay Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuVasive -1.70% 12.49% 4.71%
Bluejay Diagnostics N/A -47.07% -43.59%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NuVasive and Bluejay Diagnostics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuVasive 0 4 5 0 2.56
Bluejay Diagnostics 0 0 0 0 N/A

NuVasive presently has a consensus price target of $51.62, suggesting a potential upside of 15.24%. Given NuVasive’s higher possible upside, analysts clearly believe NuVasive is more favorable than Bluejay Diagnostics.

Insider and Institutional Ownership

0.9% of Bluejay Diagnostics shares are held by institutional investors. 0.5% of NuVasive shares are held by company insiders. Comparatively, 45.3% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

NuVasive has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

About NuVasive

(Get Rating)

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

About Bluejay Diagnostics

(Get Rating)

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with's FREE daily email newsletter.